ArticlemedRxiv : the preprint server for health sciences2025
A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: The classical "seed and soil" hypothesis suggests that metastatic spread is shaped by tumor-intrinsic traits ("seeds") and the organ-specific microenvironment ("soil"). We expand this concept to explain lesion-level therapeutic responses and phenotypic variability across metastatic cancers. Methods: We analyzed 55,220 lesions from 6,087 patients enrolled in 20 clinical trials across six cancer types. Using nonlinear mixed-effects modeling, we estimated lesion-specific parameters: regression rate (kkill), progression rate (kge), and resistant fraction (Fx). Multivariable Cox models, adjusted for cancer type, treatment modality, and clinical covariates, were used to assess organ-specific response patterns. Two key microenvironmental features-Vascular Perfusion and Leakiness Index (VaPLI) and tissue immune tolerance-were evaluated as predictors of lesion-level phenotypes. Results: Treatment response dynamics varied significantly across metastatic sites, even within the same cancer type and therapy. Lesion-level responses reflected a strong seed-soil interaction, influenced by treatment modality. Liver metastases showed high initial regression but rapid progression, while bone lesions, especially in prostate cancer, exhibited more stable responses. VaPLI and immune tolerance status were significant predictors of lesion behavior. Conclusions: Our findings support an expanded seed-soil framework that incorporates physiological and therapeutic context, enabling site-aware treatment strategies and refined patient selection for metastatic cancer therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.